IMUGENE CHART. TA only, page-24077

some news
enjoy
ac

Phase 1 clinical trial for Solid Tumour Therapy (partnership with Imugene)

At this stage, the partnership is focused on completing proof of concept studies which can then be used to commence phase 1 clinical trials, the process usually follows this route:

• Prove its most promising treatment works in a test tube - ALA and Imugene have already done this - see our Quick Take on that news here: Arovella and Imugene therapy kills cancer in a test tube

• Prove its most promising treatment works in mice - The next step after test tube studies, this will see how the treatment works and if it is safe in a living organism (in vivo - mice studies)

Bonus: Advance treatment #2 (ALA 104, DKK1-CAR-iNKT)

This is an additional treatment, but for now ALA’s latest timeline seems to be prioritising ALA-101 and the Imugene partnership treatment for solid tumours.

NEW: Enter into definitive licensing agreement for “booster tech”

Yesterday, ALA revealed that new data from experiments indicate that its iNKT platform technology can be enhanced by another complementary technology (read more in our latest ALA Quick Take).

The data has come in looking positive, so now we will be looking to see if ALA enters into a definitive licence agreement to formalise ALA’s IP position with this tech.

Below is the timeline that ALA is currently working with: